Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
474.6 USD | +0.20% | -1.21% | +16.91% |
17/06 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
14/06 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.91% | 12TCr | |
+19.11% | 11TCr | |
+2.42% | 2.27TCr | |
-16.77% | 2.13TCr | |
-39.57% | 1.69TCr | |
-14.17% | 1.67TCr | |
-16.31% | 1.66TCr | |
+2.72% | 1.36TCr | |
+21.30% | 1.1TCr | |
+108.71% | 1.04TCr |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing